Study design and setting
mental illness, communication impairment, cognitive decline, stroke, loss of consciousness, dementia, MCI, Dementia, visual and auditory)
STROKE
We conducted a double-blind, two-armed, parallel group randomised controlled trial with repeated measures to examine the effects of MCFT for older adults with MCI and mild dementia. We registered the study with the Chinese Clinical Trial Registry (ChiCTR2000039306, 5 November 2020), recruiting the first participant on 16 November 2020.We recruited older adults aged ≥65 years with MCI and mild dementia from nine community care centres in Northern Taiwan between November 2020 and March 2022, where trained interviewers screened the participants for eligibility. Then, the participants were informed of the study’s aim and methods and asked to sign a consent form. We collected the participants’ demographic and sensory function (visual and auditory) data through structured questionnaires. We included older adult ≥65 years, provided they had a Clinical Dementia Rating (CDR) of 0.5 or 1 point, were able to move independently and had no physical disabilities, were able to communicate, and wished to participate voluntarily after providing informed consent. We excluded individuals with a history of other cognitive, memory, attention, or coordination training in the previous year, history of head trauma, loss of consciousness, stroke, or rapid cognitive decline, diagnosis of severe mental illness or behavioural problem resulting in the inability to undergo training, and severe visual, hearing, or communication impairment.